EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intranasal Dry Powders as Dosage Forms: Formulation Aspects and Pharmacokinetic Evaluation Techniques

Carmen Schoeman, Suzanne Elaine van Niekerk, Anja Haasbroek-Pheiffer, Hannlie Hamman, Josias Hamman

Scientia Pharmaceutica · 30.10.2026 · 94 (4) · 101

DOI: 10.3390/scipharm94040101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 30.10.2026. Verfasst von Carmen Schoeman und 4 weiteren Autor:innen. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of South Africa.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intranasal dry powder dosage forms have attracted interest in the last decade due to their advantages over liquid nasal dosage forms. These advantages include increased residence time in the nasal cavity, greater chemical stability and improved bioavailability for some drugs. Particle properties (e.g., particle size and morphology) of intranasal dry powder formulations play a vital role in the aerodynamic behaviour and consequently the deposition site of particles in the nasal cavity, which impacts drug delivery efficiency. Furthermore, the device used to administer the intranasal dry powder should be carefully selected, as it can influence particle deposition and ultimately therapeutic outcome. Certain challenges exist when evaluating the pharmacokinetic properties of intranasal dry powder formulations using in vitro and ex vivo models, such as uneven coverage of the epithelial surface and maintenance of membrane integrity. Furthermore, due to anatomical differences, some in vivo animal models may overestimate the drug delivery performance of intranasally administered dry powders (especially nose-to-brain drug delivery) and therefore have limited translational value. Although regulatory criteria for intranasal dry powders are available, specific and harmonised guidance on the formulation and evaluation of these dosage forms is still lacking. This review provides insights into key aspects of intranasal dry powder dosage forms, including formulation aspects, particle engineering strategies, the role of dry powder delivery devices, regulatory aspects and models available for the evaluation of the pharmacokinetic properties of intranasal dry powder dosage forms.

Förderung

  • National Research Foundation of South Africa

Zitieren

APA

Schoeman, C., Niekerk, S. E. V., Haasbroek-Pheiffer, A., Hamman, H., & Hamman, J. (2026). Intranasal Dry Powders as Dosage Forms: Formulation Aspects and Pharmacokinetic Evaluation Techniques. Scientia Pharmaceutica, 94(4), 101. https://doi.org/10.3390/scipharm94040101

Vancouver

Schoeman C, Niekerk SEV, Haasbroek-Pheiffer A, Hamman H, Hamman J. Intranasal Dry Powders as Dosage Forms: Formulation Aspects and Pharmacokinetic Evaluation Techniques. Scientia Pharmaceutica. 2026;94(4):101. doi:10.3390/scipharm94040101

BibTeX
@article{Schoeman2026,
  author = {Schoeman, Carmen and Niekerk, Suzanne Elaine van and Haasbroek-Pheiffer, Anja and Hamman, Hannlie and Hamman, Josias},
  title = {Intranasal Dry Powders as Dosage Forms: Formulation Aspects and Pharmacokinetic Evaluation Techniques},
  journal = {Scientia Pharmaceutica},
  year = {2026},
  volume = {94},
  number = {4},
  pages = {101},
  doi = {10.3390/scipharm94040101}
}
Kostenlos starten →